Table 1.
Characteristics of Solid Organ Transplant Patients and Plasma Samples
| Patient information | Plasma sample information | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Median (range) age, y; Sex | CMV donor (D) / recipient (R) serostatus | Allograft type | No. of sample tested | Median (range) time after transplant, mo | Median (range) sample numbers/ patient | Median (range) CMV DNA load, log10 copies/mL |
Median (range) storage time, y | Receiving antiviral therapy, no. (%)a | |
| Group1 n = 20 |
57 (8–76) F = 6 M = 14 |
D+/R−: n = 10; D+/R+: n = 7; D−/R+: n = 2; D−/R−: n = 1 |
Kidney: n = 9; Lung: n = 6; Heart: n = 3; Liver: n = 2 |
n = 103 | 4 (1–6) | 5 (3–9) | 4.46 (2.97–6.99) |
4.5 (1–7) | 70 (68%) (40 R− and 30 R+) |
| Group 2 n = 10 |
60 (3–69) F = 6 M = 4 |
D+/R−: n = 6; D+/R+: n = 3; D−/R+: n = 1 |
Kidney: n = 2; Lung: n = 5; Liver: n = 2; Heart: n = 1 |
n = 10 | 6 (2–72) | 1 | 3.26 (2.80–5.89) |
Not applicable | 5 (50%) (4 R− and 1 R+) |
| Group 3 n = 12 |
55 (4–73) F = 7 M = 6 |
D+/R−: n = 7; D+/R+: n = 3; D−/R−: n = 1; D−/R+: n = 1 |
Kidney: n = 6; Lung: n = 3; Heart: n = 2; Liver: n = 1 |
n = 20 | 12 (2–54) | 1 (1–3) | 6.00 (4.88–6.40) |
1.5 (0.1–6) | 11 (55%) (6 R− and 5 R+) |
aAt the time of sample collection, the patient was on intravenous ganciclovir, intravenous foscarnet, or oral valganciclovir.